Literature DB >> 17998692

A new indication of sildenafil in medicine: hypoxic cell sensitizer for penile cancer.

Nagraj G Huilgol1, Amit Jain.   

Abstract

PURPOSE: To evaluate the feasibility and results of sildenafil used as radiosensitizer by causing penile vasodilatation and reducing tumor hypoxia in radical radiotherapy for penile cancer.
MATERIALS AND METHODS: Three men with histopathologic diagnosis of squamous carcinoma of penis were treated with radical external radiotherapy with concomitant sildenafil. Acute and late adverse events were noted according to RTOG toxicity criteria. Response to radiotherapy, as well as disease-free and overall survivals, was evaluated.
RESULTS: All three patients achieved tumescence, completed the treatment and achieved complete response. One patient had recurrence at 10 months and died of the disease after 23 months from starting the treatment. Other two patients are disease-free and alive at 48 and 53 months respectively. No excess acute or late adverse event was observed.
CONCLUSION: Sildenafil may act as radiosensitizer by causing penile vasodilatation and reducing hypoxia. Larger controlled studies are required to validate the hypothesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17998692     DOI: 10.4103/0973-1482.27589

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  2 in total

1.  The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.

Authors:  Donald T Weed; Serena Zilio; Isildinha M Reis; Zoukaa Sargi; Marianne Abouyared; Carmen R Gomez-Fernandez; Francisco J Civantos; Carla P Rodriguez; Paolo Serafini
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

2.  Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

Authors:  Pan Pantziarka; Vidula Sukhatme; Sergio Crispino; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2018-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.